BioCentury
ARTICLE | Clinical News

Erytech's Graspa misses in Phase IIb AML study

December 14, 2017 5:13 PM UTC

Erytech Pharma S.A. (Euronext:ERYP; NASDAQ:ERYP) reported top-line data showing that Graspa eryaspase (ERY-ASP, ERY001) missed the primary endpoint in a Phase IIb trial to treat newly diagnosed acute myelogenous leukemia (AML) in patients ineligible for intensive chemotherapy. On the 123-patient trial's primary endpoint, Graspa plus low-dose cytarabine failed to improve overall survival (OS) vs. cytarabine alone (HR=1.06, 95% CI: 0.7, 1.61). Erytech said the median duration of treatment was less than two months for both arms.

Secondary endpoints in the open-label, European trial include progression free survival (PFS), overall response rate (ORR) and safety...